PPIDT00243

Drug Information
NameAflibercept
SequenceSDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
DrugBank_IDDB08885
Typebiotech
IndicationThe opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).[L45136] The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.[L45141]
Dosage Forms
Form Route Strength
Injection Intravitreal
Injection Intravitreal
40 MG/ML
Injection, solution Intravitreal
114.3 mg/ml
Injection, solution Intravitreal
40 MG/ML
Injection, solution Intravitreal
40 mg/1mL
Solution Intravitreal
2 mg / 0.05 mL
Injection, solution Intravitreal
8 mg/0.07mL
Solution Intravitreal
8 mg / 0.07 mL
Injection, solution Intravitreal
2.0 mg/50mcl
Solution Intraocular
200000 mg
Injection, solution Intravitreal
2 mg/0.05mL
Solution Intraocular
11.120 mg
Injection Intravenous
25 MG/ML
Injection, solution, concentrate Intravenous
25 mg/1ml
Injection, solution, concentrate Intravenous
25 mg/ml
Injection, solution, concentrate Intravenous; Parenteral
25 MG/ML
Solution Intravenous
100 mg / 4 mL
Solution Intravenous
200 mg / 8 mL
Solution, concentrate Intravenous
100 mg/4mL
Solution, concentrate Intravenous
200 mg/8mL
Injection Parenteral
100 mg/4ml
Injection Parenteral
Injection, solution, concentrate Intravenous
200 mg/8ml
Injection, solution, concentrate Intravenous
Solution Intravenous
25.0 mg/ml
Solution Intravenous
25.000 mg
Solution Ophthalmic
40 mg/1ml
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P15692 VEGFA Vascular endothelial growth factor A, long form Homo sapiens inhibitor|binder Link
target P49763 PGF Placenta growth factor Homo sapiens inhibitor|binder Link
target P49765 VEGFB Vascular endothelial growth factor B Homo sapiens inhibitor|binder Link